These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22843491)

  • 41. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
    Jaeckel E; Mpofu N; Saal N; Manns MP
    Horm Metab Res; 2008 Feb; 40(2):126-36. PubMed ID: 18283631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of New Onset Type 1 Diabetes by Oral
    Mbongue JC; Rawson J; Garcia PA; Gonzalez N; Cobb J; Kandeel F; Ferreri K; Husseiny MI
    Front Immunol; 2019; 10():320. PubMed ID: 30863412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treg vaccination in autoimmune type 1 diabetes.
    Serr I; Weigmann B; Franke RK; Daniel C
    BioDrugs; 2014 Feb; 28(1):7-16. PubMed ID: 23959795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Thymic Output of Effector CD4
    Zhao Y; Alard P; Kosiewicz MM
    J Immunol Res; 2019; 2019():8785263. PubMed ID: 31281853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?
    Gagliani N; Ferraro A; Roncarolo MG; Battaglia M
    Immunol Lett; 2009 Dec; 127(1):1-7. PubMed ID: 19643137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Restoring tolerance to β-cells in Type 1 diabetes: Current and emerging strategies.
    Carroll KR; Katz JD
    Cell Immunol; 2022 Oct; 380():104593. PubMed ID: 36081179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics.
    You S; Chatenoud L
    Methods Mol Biol; 2016; 1371():117-42. PubMed ID: 26530798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
    Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
    Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.
    Cabrera SM; Rigby MR; Mirmira RG
    Curr Mol Med; 2012 Dec; 12(10):1261-72. PubMed ID: 22709273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes.
    Battaglia M; Roncarolo MG
    Semin Immunol; 2011 Jun; 23(3):182-94. PubMed ID: 21831659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes.
    Ihantola EL; Viisanen T; Gazali AM; Näntö-Salonen K; Juutilainen A; Moilanen L; Rintamäki R; Pihlajamäki J; Veijola R; Toppari J; Knip M; Ilonen J; Kinnunen T
    J Immunol; 2018 Aug; 201(4):1144-1153. PubMed ID: 30006377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.
    Jeker LT; Bour-Jordan H; Bluestone JA
    Cold Spring Harb Perspect Med; 2012 Mar; 2(3):a007807. PubMed ID: 22393537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo.
    Tonkin DR; He J; Barbour G; Haskins K
    J Immunol; 2008 Oct; 181(7):4516-22. PubMed ID: 18802054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice.
    Sgouroudis E; Albanese A; Piccirillo CA
    J Immunol; 2008 Nov; 181(9):6283-92. PubMed ID: 18941219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.
    Pesenacker AM; Wang AY; Singh A; Gillies J; Kim Y; Piccirillo CA; Nguyen D; Haining WN; Tebbutt SJ; Panagiotopoulos C; Levings MK
    Diabetes; 2016 Apr; 65(4):1031-9. PubMed ID: 26786322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule.
    Christen U; Kimmel R
    Front Endocrinol (Lausanne); 2020; 11():591083. PubMed ID: 33193102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Innate inflammation drives NK cell activation to impair Treg activity.
    Dean JW; Peters LD; Fuhrman CA; Seay HR; Posgai AL; Stimpson SE; Brusko MA; Perry DJ; Yeh WI; Newby BN; Haller MJ; Muir AB; Atkinson MA; Mathews CE; Brusko TM
    J Autoimmun; 2020 Mar; 108():102417. PubMed ID: 32035746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulation Followed by Antigen-Specific T
    Cabello-Kindelan C; Mackey S; Sands A; Rodriguez J; Vazquez C; Pugliese A; Bayer AL
    Diabetes; 2020 Feb; 69(2):215-227. PubMed ID: 31712320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered Suppressor Function of Regulatory T Cells in Type 1 Diabetes.
    Aghili B; Amirzargar AA; Rajab A; Rabbani A; Sotoudeh A; Assadiasl S; Larijani B; Massoud A
    Iran J Immunol; 2015 Dec; 12(4):240-51. PubMed ID: 26714416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in Maturation Status and Immune Phenotypes of Circulating Helios
    Zhang Y; Zhang J; Shi Y; Shen M; Lv H; Chen S; Feng Y; Chen H; Xu X; Yang T; Xu K
    Front Immunol; 2021; 12():628504. PubMed ID: 34054801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.